BioAtla, Inc. is a leading biopharmaceutical company headquartered in San Diego, California, dedicated to advancing innovative antibody-based therapies for cancer treatment. The firm leverages its proprietary Bispecific T cell Engager (BiTEx™) technology to develop targeted therapeutics that aim to selectively eliminate cancer cells with minimal harm to surrounding healthy tissue. With a strong pipeline of promising product candidates, BioAtla is strategically positioned to address unmet medical needs in oncology, showcasing its commitment to transforming cancer care and improving patient outcomes in a rapidly evolving therapeutic landscape. Show more

Location: 11085 TORREYANA ROAD, SAN DIEGO, CA, UNITED STATES, 92121, San Diego, CA, 92121, USA | Website: https://www.bioatla.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

12.17M

52 Wk Range

$0.14 - $1.43

Previous Close

$0.19

Open

$0.19

Volume

3,003,060

Day Range

$0.19 - $0.22

Enterprise Value

11.09M

Cash

8.32M

Avg Qtr Burn

-9.881M

Insider Ownership

11.08%

Institutional Own.

28.85%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ozuriftamab vedotin (BA3021) (CAB-ROR2-ADC) Details Squamous cell carcinoma of the head and neck (SCCHN)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evalstotug (BA3071) + Pembrolizumab Details Cancer, Melanoma	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ozuriftamab vedotin (BA3021) (ROR2-ADC) Details Cancer, Melanoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mecbotamab vedotin (BA3011) (anti-AXL ADC) Details Solid tumor/s, Soft tissue sarcoma, Non-small cell lung carcinoma, Bone sarcoma, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CAB-EpCAM x CAB-CD3 TCE (BA3182) Details Carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Evalstotug (BA3071) (CAB anti-CTLA-4 antibody) w/ nivolumab Details Solid tumor/s, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.